Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
McKesson
Cipla
Merck
Express Scripts
US Department of Justice
Boehringer Ingelheim
Fuji
Teva

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,246,925

« Back to Dashboard

Summary for Patent: 5,246,925
Title: 19-nor-vitamin D compounds for use in treating hyperparathyroidism
Abstract:This invention provides a novel class of vitamin D-related compounds, namely the 1.alpha.-hydroxy-19-nor-vitamin D analogs, as well as a general method for their chemical synthesis. The compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells, including malignant cells, and in inducing their differentiation, and thus represent novel therapeutic agents for the treatment of malignant and other diseases characterized by the proliferative growth of undifferentiated cells. Formulations for therapeutic use and treatment methods are also provided.
Inventor(s): DeLuca; Hector F. (Deerfield, WI), Schnoes; Heinrich K. (Madison, WI), Perlman; Kato L. (Madison, WI), Sicinski; Rafal R. (Warsaw, PL), Prahl; Jean M. (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation (Madison, WI)
Application Number:07/960,241
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 5,246,925

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,246,925

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 69006052 ➤ Try a Free Trial
Germany 69130497 ➤ Try a Free Trial
Germany 122006000018 ➤ Try a Free Trial
Denmark 0474517 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Teva
Accenture
Fish and Richardson
US Army
Baxter
Mallinckrodt
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.